Vitura Health Limited
AASX:VIT0.02
AUD
+0.00
(+5.88%)
ISIN
AU0000266801
Return %
Stock
S&P 500
1Y
-73.91
14.20
3Y
-95.26
81.12
5Y
-89.09
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Justin James
- Full Time Employees
- 72
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Suite 21, Level 3 South Yarra VIC Australia 3141
- IPO Date
- Nov 7, 2019
- Website
- vitura.com.au
- Similar Companies
- Business
- Vitura Health Limited (ASX:VIT) operates as a diversified digital health company focused on medicinal cannabis, psychedelics, and telehealth services in Australia. The company provides an integrated ecosystem connecting patients, prescribers, pharmacists, and suppliers through core offerings including the Canview digital health platform for prescribing, dispensing, and medication management of alternative therapies; telehealth consultations via Doctors on Demand for primary and on-demand virtual healthcare and Cannadoc Health (75.5% owned) for medicinal cannabis services; CDA Clinics for medicinal consultations and prescriptions; distribution of medical products such as medicinal cannabis, psychedelic drugs, and smoking cessation aids through Burleigh Heads Cannabis (BHC); psychedelics under the Cortexa brand, a 50:50 joint venture supplying GMP psilocybin and MDMA for therapeutic use outside clinical trials under Australia's Authorised Prescriber Scheme; consumer non-medical products via Adaya featuring hybrid formulations and Australian-cultivated items; and additional manufacturing partnerships including Optima for GMP clinical-grade pharmaceuticals and a Canadian joint venture with PharmAla Biotech for supply chain independence. Vitura Health conducts operations primarily in Australia with consumer product sales extending to Asia, targeting prescribers, patients, pharmacies, and suppliers in the alternative and emerging therapeutics sector. Founded in 2018 and headquartered in South Yarra, Victoria, the company, formerly Cronos Australia Limited until its name change in February 2023, employs around 121 people across its portfolio of subsidiaries. Recent developments include the February 2025 completion of the $5.9 million acquisition of Candor Medical (Livelihood Health Pty Ltd), a leading medicinal cannabis telehealth clinic, funded partly by a $5.1 million placement to AFO Investments and integrating into the Specialty Clinics division to boost annual consultations beyond 100,000 excluding Doctors on Demand; Cortexa milestones in supplying GMP psilocybin therapeutically for the first time in Australia outside trials; a strategic reset with new leadership driving business diversification and H1 FY2025 revenue growth; and board refreshments in late 2024 with new non-executive directors including Shane Francis Tanner, Rebecca Jayne Wilson, Gerard Paul Fogarty, and Daniel Francis Birch.